跳至主要内容
临床试验/NCT06521541
NCT06521541招募中不适用

Whole Course Multi-model Prehabilitation to Improve Clinical Outcome in Patients Undergoing Neoadjuvant Treatment Prior to Gastrectomy : A Single Center Randomized Control Trial

The Affiliated Hospital of Qingdao University1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
90
试验地点
1
主要终点
Cardiopulmonary capacity

研究概览

简要总结

The intention of research is to establish a multimodal prehabilitation protocol in patients who undergo neoadjuvant chemotherapy prior to gastrectomy, explore the feasibility and effectiveness of the measures and evaluate the effect of program on short-term clinical outcome, fitness and long-term prognosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥18 years;
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤2;
  • Endoscopic biopsies were pathologically confirmed as gastric adenocarcinoma;
  • The feasibility of neoadjuvant therapy was suggested by MDT, and the feasibility of radical gastrectomy was re-evaluated after neoadjuvant therapy;
  • Blood routine, liver function, kidney function, heart function and lung function were normal before neoadjuvant therapy, and there was no contraindication of chemotherapy and surgery;
  • The pregnancy test was negative within 1 month, and she was not pregnant or breastfeeding;
  • Informed consent and ability to comply with research protocols.

排除标准

  • metastasis;
  • End-stage cardiac insufficiency (LVEF<30% or NYHA class IV), liver cirrhosis (Child-Pugh classification C), End-stage renal failure (receives chronic dialysis), or ASA grade IV;
  • Cerebral hemorrhage, cerebral infarction, TIA or central nervous system disease or mental illness within 6 months, could not cooperate with the completion of neoadjuvant therapy and pre-rehabilitation exercise;
  • Patients have severe infections (such as MODS, etc.) or have allergic reactions to chemotherapy drugs and metabolic disorders;
  • Concurrent tumors or other diseases requiring simultaneous surgery (except laparoscopic gallbladder surgery);
  • Emergency surgery is required due to tumor complications (e.g., bleeding, perforation, obstruction);
  • Patients participating in other clinical trials.

结局指标

主要结局

Cardiopulmonary capacity

时间窗: Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2)

The 6-minute walk test (6MWT) can be used to measure exercise capacity to reflect cardiopulmonary function.

次要结局

  • Patient's quality of life(Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2))
  • Serum albumin levels(Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2))
  • First liquid diet(Postoperative (≤30 days after surgery))
  • 3-year overall survival(3 years)
  • sarcopenia(Baseline (T0), Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks), and prior to surgery(T2))
  • Duration of postoperative hospital stay(Postoperative (≤30 days after surgery))
  • 3-year recurrence-free survival(3 years)
  • First exhaust and defecation(Postoperative (≤30 days after surgery))
  • The incidence of postoperative complications(Postoperative (≤30 days after surgery))
  • completetion of neoadjuvant chemotherapy(Post-neoadjuvant chemotherapy (through completetion of neoadjuvant therapy, an average of 16 weeks))
  • Hospitalization costs(Postoperative (≤30 days after surgery))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验